Abstract
The biological role of vitamin D outside of calcium homeostasis is still under evaluation. The ability of vitamin D to inhibit cell proliferation and induce differentiation makes it a potential modifier of neoplastic transformation. Vitamin D affects the cell cycle, apoptosis, hormone receptors, angiogenesis, and hypoxia, all of which are related to the breast cancer growth, progression and metastasis. A large percentage of the industrial-world population is deficient in vitamin D. Epidemiological evidence suggests that vitamin D deficiency increases the risk of breast cancer. Vitamin D may have synergistic, additive, or antagonistic effects when combined with other therapeutic agents against breast cancer. Vitamin D appears to depress aromatase inhibitor by acting through cytochrome P 450. This evidence along with pre-clinical and clinical studies, justify the inclusion of vitamin D in future clinical trials related to breast cancer in order to determine its efficacy as a part of the breast cancer therapeutic armament.
Similar content being viewed by others
References
Mason JB, Hay RW, Leresche J et al (1974) The story of vitamin D: from vitamin to hormone. Lancet 1:325–329
Horst RI, Reinhardt TA (1997) Vitamin D metabolism. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 13–32
Pike JW (1992) Molecular mechanisms of cellular response to the vitamin D3 hormone. In: Coe FI, Fauus MJ (eds) Disorders of bone and mineral metabolism. Raven Press Ltd, New York, pp 163–193
Dampster DW (1992) Bone remodeling. In: COE FL, Favus MJ (eds) Disorders of bone and mineral metabolism. Ravena Press Ltd, New York, pp 355–380
DeLuca HF, Schnoes HK (1976) Metabolism and mechanism of action of vitamin D. Annu Rev Biochem 45:631–666
Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240:889–895
Van Leeuwen JPTM, OPols HAP (1997) Vitamin D: anti-cancer differentiation. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, CA, pp 1089–1106
Amento EP (1987) Vitamin D and the immune system. Steroids 49:55–72
Garland FC, Garland CF, Gorham ED et al (1990) Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 19:614–622
Sturgeon SR, Schairer C, Gail M et al (1995) Geographic variation in mortality from breast cancer among white women in the United States. J Natl Cancer Inst 87:1846–1853
Gorham ED, Garland FC, Garland CF (1990) Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 19:820–824
Cancer mortality maps & graphs. Bethesda, MD: National Cancer Institute. (http://cancercontrolplanet.cancer.gov/atlas/index.jsp)
Grant WB (2002) An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 94:1867–1875
Mohr SB, Garland CF, Gorham ED et al (2008) Relationship between low ultraviolet B irradiance and higher breast cancer risk in 107 countries. Breast J 14:255–260
Knekt P, Jarvinen R, Seppanen R et al (1996) Intake of dairy products and the risk of breast cancer. Br J Cancer 73:687–691
John EM, Schwartz GG, Dreon DM et al (1999) Vitamin D, breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971–1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 8:399–406
Lin J, Manson JE, Lee IM et al (2007) Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 167:1050–1059
Berube S, Diorio C, Verhoek-Oftedahl W et al (2004) Vitamin D, calcium, and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 13:1466–1472
Brisson J, Berube S, Diorio C et al (2007) Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev 16:929–933
Garland CF, Gorham ED, Mohr SB et al (2007) Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 103:708–711
Abbas S, Chang-Claude J, Linseisen J (2008) Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer 124:250–255
Abbas S, Linseisen J, Slanger T et al (2008) Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 29:93–99
Blackmore KM, Lesosky M, Barnett H et al (2008) Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol 168:915–924
Gissel T, Rejnmark L, Mosekilde L et al (2008) Intake of vitamin D and risk of breast cancer—a meta-analysis. J Steroid Biochem Mol Biol 111:195–199
Neuhouser ML, Sorensen B, Hollis BW et al (2008) Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 88:133–139
Sinotte M, Rousseau F, Ayotte P et al (2008) Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population. Endocr Relat Cancer 15:975–983
Trabert B, Malone KE, Daling JR et al (2007) Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case-control study of Caucasian and African-American women. Breast Cancer Res 9:R84
Colston K, Colston MJ, Feldman D (1981) 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108:1083–1086
Miyaura C, Abe E, Kuribayashi T et al (1981) 1alpha,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 102:937–943
Abe E, Miyaura C, Sakagami H et al (1981) Differentiation of mouse myeloid leukemia cells induced by 1alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 78:4990–4994
Eisman JA, Sutherland RL, McMenemy ML et al (1989) Effects of 1,25-dihydroxyvitamin D3 on cell-cycle kinetics of T 47D human breast cancer cells. J Cell Physiol 138:611–616
Simboli-Campbell M, Narvaez CJ, Tenniswood M et al (1996) 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 58:367–376
Simboli-Campbell M, Narvaez CJ, van Weelden K et al (1997) Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42:31–41
Lazzaro G, Agadir A, Qing W et al (2000) Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur J Cancer 36:780–786
Narvaez CJ, Welsh J (2001) Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 276:9101–9107
Kemmis CM, Salvador SM, Smith KM et al (2006) Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 136:887–892
Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y et al (2007) Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 75:193–207
Wu G, Fan RS, Li W et al (1997) Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene 15:1555–1563
Verlinden L, Verstuyf A, Convents R et al (1998) Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 142:57–65
Mathiasen IS, Lademann U, Jaattela M (1999) Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59:4848–4856
Swami S, Krishnan AV, Feldman D (2000) 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 6:3371–3379
Stoica A, Saceda M, Fakhro A et al (1999) Regulation of estrogen receptor-alpha gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells. J Cell Biochem 75:640–651
Campbell MJ, Gombart AF, Kwok SH et al (2000) The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 19:5091–5097
Saunders DE, Christensen C, Wappler NL et al (1993) Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 4:201–208
Maruyama R, Aoki F, Toyota M et al (2006) Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res 66:4574–4583
Kommagani R, Caserta TM, Kadakia MP (2006) Identification of vitamin D receptor as a target of p63. Oncogene 25:3745–3751
Kemmis CM, Welsh J (2008) Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway. J Cell Biochem 105:980–988
Berger U, Wilson P, McClelland RA et al (1987) Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Res 47:6793–6799
Friedrich M, Axt-Fliedner R, Villena-Heinsen C et al (2002) Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer. Histochem J 34:35–40
Zinser G, Packman K, Welsh J (2002) Vitamin D(3) receptor ablation alters mammary gland morphogenesis. Development 129:3067–3076
Zinser GM, Welsh J (2004) Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. Mol Endocrinol 18:2208–2223
Zinser GM, Welsh J (2004) Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis 25:2361–2372
Zinser GM, Suckow M, Welsh J (2005) Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J Steroid Biochem Mol Biol 97:153–164
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186
Schneider BP, Miller KD (2005) Angiogenesis of breast cancer. J Clin Oncol 23:1782–1790
Mantell DJ, Owens PE, Bundred NJ et al (2000) 1alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214–220
Ben-Shoshan M, Amir S, Dang DT et al (2007) 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 6:1433–1439
Jurutka PW, Whitfield GK, Hsieh JC et al (2001) Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord 2:203–216
Solomon C, Kremer R, White JH et al (2001) Vitamin D resistance in RAS-transformed keratinocytes: mechanism and reversal strategies. Radiat Res 155:156–162
Iqbal SJ (1994) Vitamin D metabolism and the clinical aspects of measuring metabolites. Ann Clin Biochem 31(Pt 2):109–124
Hollis BW (2004) Editorial: the determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 89:3149–3151
Bikle DD, Gee E, Halloran B et al (1986) Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 63:954–959
Heaney RP (2008) Vitamin D in health and disease. Clin J Am Soc Nephrol 3:1535–1541
Whyte MP, Haddad JG Jr, Walters DD et al (1979) Vitamin D bioavailability: serum 25-hydroxyvitamin D levels in man after oral, subcutaneous, intramuscular, and intravenous vitamin D administration. J Clin Endocrinol Metab 48:906–911
Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281
Koutkia P, Chen TC, Holick MF (2001) Vitamin D intoxication associated with an over-the-counter supplement. N Engl J Med 345:66–67
Adams JS, Lee G (1997) Gains in bone mineral density with resolution of vitamin D intoxication. Ann Intern Med 127:203–206
Wigington DP, Urben CM, Strugnell SA et al (2004) Combination study of 1, 24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines. Anticancer Res 24:2905–2912
Hershberger PA, Yu WD, Modzelewski RA et al (2001) Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043–1051
Koshizuka K, Koike M, Kubota T et al (1998) Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibits growth of MCF-7 human breast cancer cells in vivo. Int J Oncol 13:421–428
Koshizuka K, Koike M, Asou H et al (1999) Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat 53:113–120
Vink-van Wijngaarden T, Pols HA, Buurman CJ et al (1994) Combined effects of 1,25-dihydroxyvitamin D3 and tamoxifen on the growth of MCF-7 and ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 29:161–168
Vink-van Wijngaarden T, Pols HA, Buurman CJ et al (1994) Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 54:5711–5717
Paduch R, Kandefer-Szerszen M (2005) Vitamin D, tamoxifen and beta-estradiol modulate breast cancer cell growth and interleukin-6 and metalloproteinase-2 production in three-dimensional co-cultures of tumor cell spheroids with endothelium. Cell Biol Toxicol 21:247–256
Enjuanes A, Garcia-Giralt N, Supervia A et al (2005) Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulation. Eur J Endocrinol 153:981–988
Goodwin PJ, Ennis M, Pritchard KI et al. (2008) Frequency of vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1-3, No-1, MO BC. J Clin Oncol 26:(May 20 suppl; abstr 511)
Porojnicu AC, Dahlback A, Moan J (2008) Sun exposure and cancer survival in Norway: changes in the risk of death with season of diagnosis and latitude. Adv Exp Med Biol 624:43–54
Cannell JJ, Hollis BW, Zasloff M et al (2008) Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother 9:107–118
Lyra EC, Katayama MH, Basso RA et al (2008) Ki67 tumor expression in breast cancer post-menopausal patients following calcitriol supplementation. J Clin Oncol 26:(May 20 suppl; abstr 14612)
Acknowledgments
The valuable technical assistance of Mrs. Tammy Dohm is greatly appreciated.
Conflict of interest statement
The authors declare that they have no conflict of interest to the publication of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aung, T.T., Chandana, S.R., D’Silva, K.J. et al. The role of vitamin D in breast cancer. Oncol Rev 3, 19–25 (2009). https://doi.org/10.1007/s12156-009-0003-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12156-009-0003-x